Anticholinesterase activity of plastoquinones from Sargassum sagamianum: Lead compounds for Alzheimer's disease therapy

Phytotherapy Research

Volumn 21, Issue 5, 2007, Pages 423-426

  Byoung, Wook Choi ^a   Ryu, Geonseek ^a   Soo, Hee Park ^a   Eun, Sook Kim ^a   Shin, Jongheon ^b   Seok, Seon Ron ^c   Hyeon, Cheol Shin ^a   Bong, Ho Lee ^a  

^a Hanbat National University   (South Korea)

^b Seoul National University   (South Korea)

^c Daejeon University   (South Korea)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Cholinesterase inhibition; Plastoquinone; Sargassum sagamianum

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYMSERINE; DIHYDROMONOFARNESYLACETONE; DONEPEZIL; EDROPHONIUM; HUPERZINE A; MONOOXOFARNESYLACETONE; N1 NORCYMSERINE; PHENSERINE; PLASTOQUINONE; SARGACHROMENOL; SARGAQUINOIC ACID; SERINE DERIVATIVE; TACRINE; TOLSERINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CHOLINESTERASE INHIBITION; COLUMN CHROMATOGRAPHY; DRUG POTENCY; FRACTIONATION; IC 50; SARGASSUM;

ACETYLCHOLINESTERASE; ALKENES; ALZHEIMER DISEASE; BENZOPYRANS; BENZOQUINONES; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; PHYTOTHERAPY; SARGASSUM;

SARGASSUM SAGAMIANUM;

EID: 34248229866     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2090     Document Type: Article

References (28)

1. Bazelyansky M, Robey E, Kirsch JF. 1986. Fraction diffusion limited component of reactions catalyzed by acetylcholinesterase. Biochemistry 25: 125-130.
2. Brossi A. 1990. Bioactive alkaloids. 4. Results of recent investigations with colchicine and physostigmine. J Med Chem 33: 2311-2319.
3. Courtney C, Farrell D, Gray R et al. 2004. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363(9427): 2105-2115.
4. Cummings JL. 2000. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 157: 4-15.
5. Darvesh S, Hopkins D, Geula C. 2003. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4: 131-138.
6. Drachman DA, Leavitt J. 1974. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30: 113-121.
7. Ellmans GL, Courtney KD, Andress VJ, Featherstone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
8. Giacobini E. 2000. Cholinesterases and Cholinesterase Inhibitors. Martin Dunitz: London.
9. Greig NH, Pei X-F, Soncrant TT, Ingram DK, Brossi A. 1995. Phenserine and ring C hetero-analogs: Drug candidates for the treatment of Alzheimer's disease. Med Res Rev 15: 3-31.
10. Greig NH, Sambamurti K, Yu QS et al. 2003 Butyrylcholinesterase: its selective inhibition and relevance to Alzheimer's disease. In Butyrylcholinesterase: Its Function and Inhibition, Giacobini E (ed.). Martin Dunitz: London, 69-90.
11. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma G, Lahiri DK. 2005a. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alz Res 2: 281-291.
12. Greig NH, Utsuki T, Ingram DK et al. 2005b. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. PNAS 102: 17213-17218.
13. Greig NH, Utsuki T, Yu Q et al. 2001. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 17(2): 1-6.
14. Ishitsuka M, Kusumi T, Nomura Y, Konno T, Kakisawa H. 1979. New geranylgeranylbenzoquinone derivatives from Sargassum tortile. Chem Lett 1269-1272.
15. Kikuchi T, Yokoi T, Nakazawa S et al. 1983. Structure and absolute configuration of sargatriol, a new isoprenoid chromenol from a brown alga Sargassum tortile C. Agardh. Chem Pharm Bull 31: 106-113.
16. Kusumi T, Ishitsuka M, Nomura Y, Konno T, Kakisawa H. 1979a. New farnesylacetone derivatives from Sargassum micracanthum. Chem Lett 1181-1184.
17. Kusumi T, Shibata Y, Ishitsuka M, Kinoshita T. 1979b. Structure of new plastoquinones from the brown alga Sargassum serratifolium. Chem Lett 277-278.
18. Lahiri DK, Rogers JT, Sambamurti K, Greig NH. 2004. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 10: 3111-3119.
19. Liu JS, Zhu YL, Yu CM et al. 1986. The structures of huperzine A and B, two new alkaloids exhibiting marked anticholines-terase activity. Can J Chem 64: 837-839.
20. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. 2005. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 53: 83-87.
21. Luo W, Yu QS, Zhan M et al. 2005. Novel acetylcholinesterase based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. J Med Chem 48: 986-994.
22. Ryu G, Park SH, Kim ES, Choi BW, Lee BH. 2003. Cholinesterase inhibitory activity of two farnesyl derivatives from the brown alga Sargassum sagamianum. Arch Pharm Res 26: 796-799.
23. Sambamurti K, Greig NH, Lahiri DK. 2002. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. NeuroMol Med 1: 1-31.
24. Sambamurti K, Suram A, Venugopal C et al. 2006. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alz Res 3: 81-90.
25. Segawa M, Shirahama H. 1987. New plastoquinones from the brown alga Sargassum sagamianum var. Yezoense. Chem Lett 1365-1366.
26. Selkoe DJ. 2005. Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62: 192-195.
27. Shizuri Y, Matsukawa S, Ojika M, Yamada K. 1982. Two new farnesylacetone derivatives from the brown alga Sargassum micracathum. Phytochemistry 21: 1808-1809.
28. Yu QS, Holloway HW, Utsuki T, Brossi A, Greig NH. 1999. Synthesis of novel phenserine-based selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem 42: 1855-1861.